A significant piece of public health research, which was abruptly pulled from publication by the CDC’s leadership earlier this year, has finally reached the public domain. The study, which evaluates the effectiveness of the 2025-2026 COVID-19 vaccine, was published in JAMA Network Open, reigniting a high-stakes debate over scientific methodology, administrative oversight, and the best practices for monitoring vaccine performance in real-world settings.
The findings offer a clear look at the protective capabilities of the updated vaccine formulations, yet the path to their publication serves as a case study in the tension between academic freedom, government oversight, and the urgent need for transparent health data.
The Core Findings: Vaccine Effectiveness in the 2025-2026 Season
The research, led by Ruth Link-Gelles, PhD, MPH, of the CDC’s National Center for Immunization and Respiratory Diseases, provides crucial data regarding the clinical impact of the 2025-2026 COVID-19 vaccine series. Analyzing the first four months of the season, the study utilized a case-control design to measure how well the vaccines held up against severe outcomes.
The data indicates that the vaccine remains a powerful tool in mitigating the burden of COVID-19. Key findings include:
- Urgent Care and ED Visits: The estimated vaccine effectiveness (VE) rate against COVID-associated emergency department and urgent care visits stood at 50% (95% CI 42-57).
- Hospitalizations: The protection against COVID-associated hospitalizations was slightly higher, reaching 55% (95% CI 41-66) among the general adult population.
For the most vulnerable demographic—adults aged 65 and older—the numbers remained robust, albeit slightly lower than the general population. In this group, the estimated VE was 48% against urgent care/ED visits and 53% against hospitalizations.
Link-Gelles and her team emphasized that these findings demonstrate the "added benefit" of the 2025-2026 vaccination, regardless of an individual’s prior history of infection or previous vaccination status. "The pace and frequency with which new SARS-CoV-2 lineages have become predominant, as exemplified by the spread of the SARS-CoV-2 variant BA.3.2, underscores the value of ongoing monitoring of COVID-19 VE and genomic surveillance," the authors wrote.
Chronology of a Controversy: From MMWR to JAMA
The publication of this study was anything but routine. Originally slated for release in the CDC’s Morbidity and Mortality Weekly Report (MMWR) in March, the paper was pulled at the eleventh hour.
The rejection came directly from the CDC’s acting director, Jay Bhattacharya, MD, PhD. Bhattacharya challenged the fundamental methodology employed by the researchers: the "test-negative design" (TND). This methodology compares the vaccination status of individuals who test positive for a virus (the cases) against those who seek medical care for similar symptoms but test negative (the controls).
The Critique
Bhattacharya’s intervention centered on the validity of the TND, arguing that the design might be inherently flawed or insufficient for the current epidemiological landscape. Furthermore, his critique extended to the institutional nature of the MMWR itself. During the period of the suppression, Bhattacharya stated, "MMWR is not currently a peer-reviewed journal—but we are working on changing that."
This stance sent shockwaves through the scientific community, as MMWR has long served as the primary vehicle for the CDC to communicate rapid-response data to public health officials and clinicians. By pulling the study, the leadership effectively signaled a shift in how the CDC intends to curate and validate the data it releases to the public.
Methodology Under the Microscope: Why Test-Negative?
The debate over the test-negative design is not merely academic; it strikes at the heart of how public health agencies track diseases in the absence of perfect clinical trials.
What is the Test-Negative Design (TND)?
As explained by the researchers, the TND is a pragmatic, efficient, and well-established method for evaluating respiratory virus vaccines. It allows scientists to calculate effectiveness in real-world settings by leveraging electronic health records (EHR). Because patients who test negative for SARS-CoV-2 often share similar characteristics and health-seeking behaviors as those who test positive, they serve as a practical proxy for the source population.
Defending the Approach
In an accompanying editorial in JAMA Network Open, Natalie Dean, PhD, of the Emory Rollins School of Public Health, provided a robust defense of the TND. She noted that the method "avoids the need to establish a fully enumerated cohort of vaccinated and unvaccinated populations followed in time."
Dean pointed out that the TND has been the bedrock of influenza vaccine monitoring for decades. "The TND remains an important and practical approach while other options continue to mature," she argued. Regarding the criticisms of bias or "health-seeking behavior"—the idea that vaccinated people might be more likely to seek care when sick—Dean noted that the design itself helps mitigate these concerns by restricting the control group to those who have already entered the medical system for similar respiratory symptoms.
Furthermore, she highlighted that the CDC and other agencies perform "extensive sensitivity analyses" to check for residual confounding and ensure the robustness of the findings. The JAMA publication of this specific study—subjected to rigorous peer review—serves as an implicit validation of the design’s utility in the current medical environment.
The Broader Landscape: Public Health Implications
The significance of these findings is bolstered by the sheer scale of the study. The researchers utilized the Virtual SARS-CoV-2, Influenza, and Other Respiratory Viruses Network (VISION), incorporating data from 85,725 ED/urgent care visits and 26,073 hospitalizations. The data was drawn from 253 facilities across seven states, spanning the final four months of 2025.
The Cost of COVID-19
The necessity of this research is underscored by the CDC’s own estimates. For the 2024-2025 season, the agency reported between 390,000 and 550,000 COVID-associated hospitalizations. As of February, the 2025-2026 season was already trending toward a similar burden, with 99,000 to 180,000 hospitalizations reported by mid-season.
Evidence from three other recent studies has consistently shown that COVID-19 vaccines correlate with reduced risks of major adverse cardiovascular events, critical illnesses, and emergency care utilization. By providing further confirmation of the 2025-2026 vaccine’s effectiveness, the Link-Gelles study provides clinicians with a data-backed justification for continued vaccination programs, particularly for elderly populations.
Conclusion: The Path Forward for Scientific Communication
The journey of this study—from a rejected MMWR manuscript to a published JAMA paper—highlights a critical juncture in the history of the CDC. While the agency has a mandate to provide the most accurate, transparent, and timely information to the public, the recent internal friction regarding methodology suggests a changing approach to administrative oversight.
The scientific community remains divided on whether the current leadership’s skepticism of traditional methods like the TND is a necessary evolution toward higher evidentiary standards or an unnecessary impediment to public health communication. However, the publication of the Link-Gelles paper serves as a reminder that the demand for peer-reviewed, data-driven insights remains the ultimate filter for public health policy.
As the SARS-CoV-2 virus continues to evolve, the ability to rapidly assess vaccine performance is not just a scientific luxury; it is a clinical necessity. The debate surrounding this study underscores that for the public to maintain trust in government health institutions, the process of how data is scrutinized, challenged, and eventually released must be as transparent as the data itself. Through the lens of this publication, it is clear that while the methods of evaluation may be debated, the evidence of vaccine effectiveness remains a critical pillar in the ongoing management of COVID-19.
